Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/56052
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSantos García, D
dc.contributor.authorJesús, S
dc.contributor.authorAguilar, M
dc.contributor.authorPlanellas, L L
dc.contributor.authorGarcía Caldentey, J
dc.contributor.authorCaballol, N
dc.contributor.authorLegarda, I
dc.contributor.authorHernández Vara, J
dc.contributor.authorCabo, I
dc.contributor.authorLópez Manzanares, L
dc.contributor.authorGonzález Aramburu, I
dc.contributor.authorÁvila Rivera, M A
dc.contributor.authorCatalán, M J
dc.contributor.authorLópez Díaz, L
dc.contributor.authorPuente, V
dc.contributor.authorGarcía Moreno, J M
dc.contributor.authorBorrué, C
dc.contributor.authorSolano Vila, B
dc.contributor.authorÁlvarez Sauco, M
dc.contributor.authorVela, L
dc.contributor.authorEscalante, S
dc.contributor.authorCubo, E
dc.contributor.authorCarrillo Padilla, F
dc.contributor.authorMartínez Castrillo, J C
dc.contributor.authorSánchez Alonso, P
dc.contributor.authorAlonso Losada, M G
dc.contributor.authorLópez Ariztegui, N
dc.contributor.authorGastón, I
dc.contributor.authorKulisevsky, J
dc.contributor.authorMenéndez González, M
dc.contributor.authorSeijo, M
dc.contributor.authorRúiz Martínez, J
dc.contributor.authorValero, C
dc.contributor.authorKurtis, M
dc.contributor.authorde Fábregues-Boixar, O
dc.contributor.authorGonzález Ardura, J
dc.contributor.authorPrieto Jurczynska, C
dc.contributor.authorMartinez-Martin, P
dc.contributor.authorMir, P
dc.contributor.authorCOPPADIS Study Group
dc.date.accessioned2022-10-04T07:19:10Z-
dc.date.available2022-10-04T07:19:10Z-
dc.date.issued2019-07-04
dc.identifier.citationEur J Neurol.2019;(26)11:1399-1407
dc.identifier.urihttps://hdl.handle.net/20.500.12530/56052-
dc.description.abstractIn Parkinson's disease (PD), the course of the disorder is highly variable between patients. Well-designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim was to show the results of baseline evaluations of an ongoing global PD project, COPPADIS-2015 (Cohort of Patients with PArkinson's DIsease in Spain, 2015). This was an observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants. In total, 1174 subjects from 35 centres were considered valid for baseline analysis: 694 patients (62.6 ± 8.9 years old, 60.3% males), 273 caregivers (58.5 ± 11.9 years old, 31.8% males) and 207 controls (61 ± 8.3 years old, 49.5% males). The mean disease duration was 5.5 ± 4.4 years. Hoehn and Yahr stage was 1 or 2 in 90.7% of the patients whilst 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. The mean Non-Motor Symptoms Scale total score was 45.4 ± 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder, 7.2% compulsive behaviour, 57.2% pain and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non-motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging). Parkinson's disease is a complex disorder and different non-motor symptoms are frequently present and are more prevalent than in controls. In real clinical practice it is important to ask for them.
dc.language.isoen
dc.subjectParkinson's disease
dc.subjectgait
dc.subjectmood
dc.subjectmotor fluctuations
dc.subjectnon-motor symptoms
dc.subjectquality of life
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshCaregivers
dc.subject.meshCognition Disorders
dc.subject.meshCohort Studies
dc.subject.meshComorbidity
dc.subject.meshDisease Progression
dc.subject.meshDisruptive, Impulse Control, and Conduct Disorders
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLongitudinal Studies
dc.subject.meshMale
dc.subject.meshMental Disorders
dc.subject.meshMiddle Aged
dc.subject.meshMovement Disorders
dc.subject.meshParkinson Disease
dc.subject.meshProspective Studies
dc.subject.meshQuality of Life
dc.subject.meshSocioeconomic Factors
dc.subject.meshSpain
dc.titleCOPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015): an ongoing global Parkinson's disease project about disease progression with more than 1000 subjects included. Results from the baseline evaluation.
dc.typeArtículo
dc.identifier.pubmedID31179586
dc.format.volume26
dc.format.page1399-1407
dc.identifier.e-issn1468-1331
dc.identifier.journalEuropean journal of neurology
dc.identifier.journalabbreviationEur J Neurol
dc.identifier.doi10.1111/ene.14008
dc.format.number11
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
Appears in Collections:Fundaciones e Institutos de Investigación > FIIB H. U. Infanta Sofía y H. U. Henares > Artículos

Files in This Item:
The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.